Stories

Chicago’s life sciences ecosystem is taking off: In the first half of this year, AveXis sold for $8.7 billion, the largest acquisition of a Chicago-area biotechnology company to date. Iterum Therapeutics, Xeris Pharmaceuticals and Aptinyx all went public, as did Exicure (whose CEO, David Giljohann, will be at MATTER in October for Tales from the Trenches). Between 2013 and 2017, 44% of funding …

Read more

Bringing a new healthcare product to market is no easy task. But bringing a new healthcare product to market in another country with a different health system, regulatory environment and business landscape can be an even more daunting challenge.

To reduce the friction of entering the U.S. healthcare market, MATTER and the Consulate General of Canada work together on a mentorship program to sup…

Read more

Ten years ago, Tom Riley’s mother was diagnosed with ovarian cancer. As she embarked on her journey as a cancer patient, Mr. Riley began his journey as her caregiver and advocate.

The two quickly learned how challenging it could be to keep on top of the care plan and understand what symptoms to watch out for or whether to escalate a concern to the doctor.

“Even with two college-educated peopl…

Read more

Last November, Sangamo Therapeutics made medical history by treating the first patient with an in vivo genome-editing therapeutic delivered intravenously to “edit” cells within the patient’s body. In a recent talk at MATTER, Sangamo CEO Sandy Macrae discussed how the company’s zinc finger technology for gene editing will fundamentally change how we care for patients and treat disease. Watch the…

Read more